Recent developments in nucleic acid-based therapies for Parkinson's disease: Current status, clinical potential, and future strategies.

ABSTRACT: Parkinson's disease is the second most common progressive neurodegenerative disease diagnosed mainly based on clinical symptoms caused by loss of nigrostriatal dopaminergic neurons. Although currently available pharmacological therapies provide symptomatic relief, however, the disease continues to progress eventually leading to severe motor and cognitive decline and reduced quality of life. The hallmark pathology of Parkinson's disease includes intraneuronal inclusions known as Lewy bodies and Lewy neurites, including fibrillar α-synuclein aggregates. These aggregates can progressively spread across synaptically connected brain regions leading to emergence of disease symptoms with time. The α-synuclein level is considered important in its fibrillization and aggregation. Nucleic acid therap

SUBMITTER: Pandey SK 

PROVIDER: S-EPMC9632735 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature